Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

12h ago, source: Zacks.com on MSN

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus ...

Vertex Pharmaceuticals Inc VRTX

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Boston-based Vertex makes $4.9B acquisition, largest in its history

18d ago, source: NECN

Vertex Pharmaceuticals Inc. has agreed to buy a Seattle-based biotech developing a drug to treat kidney disease for $4.9 billion, the biggest acquisition in the Boston company’s history.

Vertex to acquire Seattle biotech for $4.9B

19d ago, source: The Business Journals

Vertex Pharmaceuticals Inc. has agreed to buy a Seattle-based biotech developing a drug to treat kidney disease for $4.9 billion, the biggest acquisition in the Boston company’s history.

$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs

on MSN ago, source:

Vertex Pharmaceuticals Inc‘s (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, ...

Vertex Pharma’s $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says

18d ago, source: MarketWatch

Vertex Pharmaceuticals Inc.’s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company’s rare-disease franchise by adding a potentially billion-dollar ...

Vertex Pharmaceuticals Stock (NASDAQ:VRTX), Analyst Ratings, Price Targets, Predictions

12d ago, source: Benzinga.com

$399.92 39.78% Goldman Sachs ...

What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences

18d ago, source: Seeking Alpha

Vertex Pharmaceuticals (NASDAQ:VRTX) announced yesterday it will acquire Alpine Immune Sciences (NASDAQ:ALPN) for $65 per share, which translates to $4.9 billion market value or $4.6 billion net ...

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

28d ago, source: Business Insider

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated ...

Vertex Pharmaceuticals, Inc.

4d ago, source: U.S. News & World Report

Sign up to receive the latest updates from U.S. News & World Report and our trusted partners and sponsors. By clicking submit, you are agreeing to our Terms and ...